Special Issue "Middle East Respiratory Syndrome Coronavirus Infection"
A special issue of Pathogens (ISSN 2076-0817).
Deadline for manuscript submissions: closed (30 June 2020).
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified as a novel human pathogen in 2012 following its isolation from a patient in Saudi Arabia that died from pneumonia and renal failure. In the time since that original description, there have been more than 2400 laboratory-confirmed human cases of infection with MERS-CoV, with a case fatality rate of approximately 34 percent. Although cases have been recognized in 27 countries, a large majority of cases have occurred and continue to occur in Saudi Arabia and adjacent countries. It is clear that human-to-human transmission of MERS-CoV occurs and poses a threat for pandemic spread, but also that this is primarily a zoonotic disease, with dromedary camels as the important reservoir host. Within Middle Eastern countries, virtually all dromedaries become infected early in life, and although the infection is mild or subclinical, the animals shed large quantities of virus from their upper respiratory tract, serving as a potent source for transmission to humans. A great deal has been learned about MERS and MERS-CoV since 2012, but numerous questions remain. For example, there is a lack of understanding of why MERS has not been recognized in East Africa, despite large populations of dromedaries that carry a MERS-CoV closely related to that from the Middle East – is this a function of viral genetics, host response or a combination of other factors? There is ongoing research to develop effective vaccines and therapeutics to mitigate human infection or perhaps even prevent infection in the reservoir host as a means of blocking zoonotic transmission; all of these efforts would benefit from an enhanced understanding of immune responses in humans and animals to MERS-CoV infection.
This Special Issue will cover a wide range of topics focusing on MERS-CoV infection and immunity, and aims to help fill the gaps in our current understanding of this pandemic threat. All types of articles will be considered for publication, including short reports, primary research articles, and reviews.
Prof. Dr. Richard A. Bowen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.